 |
|
DATE: December 16, 2025 TO: Interested Parties FROM: Lara Strawbridge, Acting Director, Medicare Drug Rebate and Negotiations Group SUBJECT: Technical Correction to Medicare Drug Price Negotiation Program Final Guidance for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price in 2026, 2027, and 2028 CMS announces that it has posted a corrected version of the Medicare Drug Price Negotiation Program Final Guidance for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price in 2026, 2027, and 2028 (Final Guidance) on the Medicare Prescription Drug Affordability website on CMS.gov.1 The updated version addresses a numerical error in the Final Guidance in footnote 93 on page 172. The footnote in the Final Guidance issued on September 30, 2025 read “The inflation-adjusted threshold for initial price applicability year 2027 was $206,680,981.” The correct number for the threshold is $206,680,891, and a technical correction to incorporate this number appears in footnote 93 of the corrected version of the Final Guidance updated on December 16, 2025. |
| Centers for Medicare & Medicaid Services (CMS) has sent this update. To contact Centers for Medicare & Medicaid Services (CMS) go to our contact us page. |
|